Jeffrey N. Peterson, CEO, brings broad executive general management, multi-functional, multi-business and international experience to Target Discovery. He spent 9 years in key management roles in Abbott Laboratories’ Diagnostics and International (Pharmaceuticals, Hospital Products, Nutritionals, Consumer) businesses. He most recently served as CEO and General Manager of Abbott South Africa, doubling the sales and tripling the income of this 50 year-old business in 3.5 years, during the tumult of South Africa’s political transition. He played an earlier pivotal management role in Abbott’s successful introduction and support of multiple new diagnostics instrument and reagent systems in the history-making X-System series, including the IMx (the highest global sales diagnostic system in history). Mr. Peterson's experience prior to Abbott included 11 years with General Electric’s Engineered Materials and Plastics businesses, spanning roles in strategic planning, business development, technology licensing, marketing/sales, operations/quality and R&D. Mr. Peterson holds BSChE and MSChE (Chemical Engineering) degrees from MIT. He serves as Chairman of the BayBio Institute, a non-profit organization serving the regional life science community, and on the Board of BayBio, the trade association for the life sciences industry in Northern California. He is a co-founder of the Coalition for 21st Century Medicine, and of BIO's Research Tools & Molecular Diagnostics Working Group.

Dr. Luke V. Schneider, CSO, brings a wealth of entrepreneurial technical experience to TDI. Prior to founding TDI, Dr. Schneider founded and served as the first Director of both the Upconverting Phosphor Diagnostics and Combinatorial Methods Centers at SRI International where he directed the work of 82 PhD’s in 11 different scientific disciplines. The phosphor technology was licensed to Orasure Technologies in 1994, which went public in October 2000. Dr. Schneider also served as SRI’s Director of Technology Development, with lead roles in several spin-off companies: Pangene (a gene therapy company), Facilichem (a liquid membrane separation company), CombiCat (a combinatorial catalysis company), and TagTech (an anti-counterfeiting technology company). Dr. Schneider serves on the board of Aromyx, Inc., which is commercializing a G-protein coupled receptor biosensor technology he invented prior to founding TDI. Dr. Schneider also managed the SRI Aerosol Drug Delivery Program, from which Inhale Therapeutics was spun out and which served as the virtual R&D and GMP manufacturing arm of Dura Pharmaceuticals. While at SRI, Dr. Schneider also led the team that won the first and was a member of the team that won the second Monsanto Million Dollar Challenges (international competitions to solve intractable hazardous chemical waste treatment problems for Monsanto). Prior to SRI, Dr. Schneider was the lead researcher in Dupont efforts in biological treatment of hazardous wastes (now out-licensed), and a member of the research team developing Group Transfer Polymerization. Dr. Schneider has 24 issued US patents (14 of which form the basis of TDI’s IP portfolio) and holds a PhD and M.A. in Chemical Engineering (Princeton University), an MSE and BSES in Chemical Engineering, and a B.A. in Biology (University of South Florida).

Dr. David C. Bomberger, Director of Operations and Manufacturing, was the Director of Formulations and ran the GMP manufacturing facility for SRI International. In this role he managed a team of formulation scientists and technicians to produce materials for both startup and national pharmaceutical companies to use in Stage I and II clinical trials. He led a team that developed a GMP system from scratch, built a clean room that produced CFC free metered dose inhalers for Dura Pharmaceuticals had major roles in programs to develop medical devices for Powderject, and Lipid Sciences. Dr. Bomberger was a team member that won the first Monsanto Million Dollar Challenge, and led the team that won the second Million Dollar Challenge. He led projects to scale up the production of specialty chemicals, pharmaceutical intermediates, and a novel rocket propellant invented at SRI. Dr. Bomberger previously worked at Shell Development Co. and Bechtel Environmental Services. He holds a Ph.D and MA in Chemical Engineering (Princeton University), a BS in Chemical Engineering, and a BA in Economics (Tufts University).